Position
Chief Medical Officer
Company
Alchemab Therapeutics
LondonBiotechnologyHealth CareTherapeuticsPharmaceuticalDescription
Alchemab Therapeutics has appointed Dr Ben Porter-Brown as Chief Medical Officer to enhance the clinical development of their innovative antibody therapeutics pipeline. This move is aimed at accelerating their research efforts in the biotechnology sector.
Quick answer
Alchemab Therapeutics Appoints Dr Ben Porter-Brown as Chief Medical Officer (September 10, 2026). Alchemab Therapeutics is based in London, England, United Kingdom.
- Who is the new Chief Medical Officer at Alchemab Therapeutics?
- Alchemab Therapeutics named Ben Porter-Brown Chief Medical Officer, announced September 10, 2026.
- What did Alchemab Therapeutics announce on September 10, 2026?
- Alchemab Therapeutics has appointed Dr Ben Porter-Brown as Chief Medical Officer to enhance the clinical development of their innovative antibody therapeutics pipeline. This move is aimed at accelerating their research efforts in the biotechnology sector.
- What does Alchemab Therapeutics do?
- Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development.
- Where is Alchemab Therapeutics based?
- Alchemab Therapeutics is based in London, England, United Kingdom.
- Which similar companies made leadership changes around the same time?
- Retension Pharmaceuticals (September 10, 2026), Abivax (September 7, 2026), Arletta Pharma Solutions (September 1, 2026) and Azora Therapeutics, Inc. (DE) (August 29, 2026) also announced leadership changes within 45 days of Alchemab Therapeutics.
Source: Fundz verified event record.
Other recent leadership changes in Therapeutics and Pharmaceutical
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- Retension Pharmaceuticals Appoints LeAnne Bloedon as EVP of Clinical Development (September 10, 2026)
- Abivax Appoints James Berger as Global Head of Marketing (September 7, 2026)
- Arletta Pharma Solutions Appoints Jeannette Jager-van Dijk as Chief Executive Officer (September 1, 2026)
- Adial Pharmaceuticals Appoints Matthew Davidson as President and CEO (August 29, 2026)
- Travere Therapeutics Appoints Bradley L. Campbell as Chief Executive Officer (September 21, 2026)
- Parabilis Medicines Appoints Craig Tendler as Director (August 25, 2026)
Who to call at Alchemab Therapeutics, and when
A new leader at Alchemab Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day Alchemab Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alchemab Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alchemab Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alchemab Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Alchemab Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.